# ClinicalIntelPulse Disease Landscape

> ClinicalIntelPulse Disease Landscape is a paid API for AI agents from clinicalintelpulse.vercel.app, paid per call via x402, $0.35/call, status unknown (last checked 2026-09-15).

Returns a complete pipeline intelligence snapshot for any disease area, covering Phase 2-3 trial map, mechanism coverage, approved therapies, PDUFA calendar, competitive gaps, and market dynamics.

## Facts

- Endpoint: GET https://clinicalintelpulse.vercel.app/api/clinical/disease-landscape
- Price: $0.35/call
- Payment: x402
- Status: unknown
- Last checked: 2026-09-15
- Activations on Zero: 0
- Tags: x402
- Canonical page: https://www.zero.xyz/c/clinicalintelpulse-disease-landscape-3e5cf534
- Structured record (JSON): https://api.zero.xyz/v1/capabilities/cap_peoUPxRgRYjhxgZJrxlc9

Status and success rate cover calls made through Zero and Zero's own probes. Third-party monitors may report differently.

## How to call it through Zero

Zero handles the 402 payment challenge and records the run. With the Zero CLI installed (`npm i -g @zeroxyz/cli`):

```sh
zero fetch --capability clinicalintelpulse-disease-landscape-3e5cf534
```

Example prompt: Give me a full pipeline intelligence report for MASH — I want the Phase 2 and 3 trial map, mechanism coverage, approved landscape, any upcoming PDUFA dates, and where the competitive gaps are.

## When to prefer this

Use this endpoint when you need a broad, synthesized intelligence snapshot across an entire disease area in one call — rather than querying individual trial details, single-company pipelines, or specific NCT IDs. Ideal for competitive landscape assessments, investment diligence, BD/licensing scans, or strategic planning where you want Phase 2-3 map, approved drugs, PDUFA dates, and competitive gaps all in one response.

## Known failure modes

- Unknown or misspelled disease name returns an error or empty results
- Very rare or newly-named diseases may have sparse pipeline data
- PDUFA calendar may be incomplete if no near-term approvals are pending
- Rate limiting or payment failure on the x402 micropayment layer
- Stale data if underlying registry sources have not been recently refreshed

## How this service works

Competitive drug pipeline landscape for any disease — full Phase 2/3 trial map, mechanism-of-action coverage, approved drugs, PDUFA calendar, M&A activity, opportunity gaps and investment thesis. Worldwide. For biotech and pharma intelligence agents.

## Output

A structured report covering: active Phase 2/3 trials in the disease area, mechanism-of-action distribution across the pipeline, approved therapy landscape, upcoming PDUFA/regulatory milestones, identified whitespace and competitive gaps, and key sponsor/competitive dynamics.

## Request schema (JSON Schema)

```json
{
 "type": "object",
 "$schema": "https://json-schema.org/draft/2020-12/schema",
 "required": [
  "input"
 ],
 "properties": {
  "input": {
   "type": "object",
   "required": [
    "type",
    "method"
   ],
   "properties": {
    "type": {
     "type": "string",
     "const": "http"
    },
    "method": {
     "enum": [
      "GET",
      "HEAD",
      "DELETE"
     ],
     "type": "string"
    },
    "queryParams": {
     "type": "object",
     "properties": {
      "lang": {
       "type": "string"
      },
      "depth": {
       "type": "string"
      },
      "condition": {
       "type": "string"
      }
     }
    }
   },
   "additionalProperties": false
  },
  "output": {
   "type": "object",
   "required": [
    "type"
   ],
   "properties": {
    "type": {
     "type": "string"
    },
    "errors": {
     "type": "object",
     "description": "Documented error responses, keyed by HTTP status code",
     "additionalProperties": {
      "type": "object",
      "required": [
       "description"
      ],
      "properties": {
       "example": {
        "type": "object"
       },
       "description": {
        "type": "string"
       }
      }
     }
    },
    "example": {
     "type": "object"
    }
   }
  }
 }
}
```

## Response schema (JSON Schema)

```json
{
 "type": "json",
 "example": {
  "deal_activity": "Highly active M&A space. AstraZeneca acquired Eccogene NASH program ($185M). Roche/Genentech building liver portfolio. Novo Nordisk GLP-1 dominance creating competitive panic.",
  "query_summary": {
   "as_of": "2026-06-07",
   "depth": "standard",
   "condition": "NASH (Nonalcoholic Steatohepatitis)"
  },
  "approved_drugs": [
   {
    "name": "Resmetirom (Rezdiffra)",
    "sponsor": "Madrigal Pharmaceuticals",
    "approved": "2024-03",
    "mechanism": "THR-β agonist",
    "indication": "NASH with moderate-to-advanced fibrosis"
   }
  ],
  "pdufa_calendar": [
   {
    "drug": "Lanifibranor",
    "sponsor": "Inventiva",
    "mechanism": "Pan-PPAR",
    "pdufa_estimate": "2026-Q1",
    "priority_review": false
   }
  ],
  "investment_thesis": "NASH market projected $18-25B by 2030. Resmetirom first approval sets pricing precedent. GLP-1 combination therapy is the likely future standard of care.",
  "opportunity_score": {
   "max": 100,
   "note": "Validated market with first approval. GLP-1 expansion threatening narrow competitors.",
   "score": 78,
   "rating": "High Value"
  },
  "pipeline_overview": {
   "phase2_count": 48,
   "phase3_count": 19,
   "total_active": 67,
   "approved_drugs": 2,
   "approval_recent_12m": 1
  },
  "top_phase3_assets": [
   {
    "drug": "Semaglutide 2.4mg",
    "nctId": "NCT04858633",
    "sponsor": "Novo Nordisk",
    "mechanism": "GLP-1 RA",
    "completion": "2025-Q4",
    "significance": "Blockbuster potential — NASH + obesity combined label"
   }
  ],
  "mechanism_landscape": {
   "crowded": [
    "FXR agonists (8 Phase 2/3)",
    "ACC inhibitors (6)",
    "FGF21 analogs (5)"
   ],
   "emerging": [
    "Pan-PPAR agonists",
    "GLP-1/GIP combinations (semaglutide expanding)"
   ],
   "opportunity_gaps": [
    "Cirrhosis reversal agents",
    "Pediatric NAFLD",
    "Combination sequential therapy protocols"
   ]
  },
  "key_readouts_next_18m": [
   "NASH-RESOLVE (semaglutide histology 2025)",
   "MAESTRO-NASH (lanifibranor 2025)",
   "ATLAS trial (aldafermin 2026)"
  ]
 }
}
```

## More

- Live health (JSON, refreshed every minute): https://www.zero.xyz/c/clinicalintelpulse-disease-landscape-3e5cf534/health.json
- [Zero catalog index](https://www.zero.xyz/llms.txt)
- [Other services from clinicalintelpulse.vercel.app](https://www.zero.xyz/host/clinicalintelpulse.vercel.app/llms.txt)